Key result
Renal denervation shows therapeutic potential in CKD, but variable efficacy and safety concerns persist.
Why the study?
Renal denervation shows therapeutic potential for patients with chronic kidney disease, yet it faces challenges including heterogeneous efficacy and potential safety concerns.
This narrative review summarizes current evidence regarding the efficacy, safety, and ongoing challenges of renal denervation in patients with chronic kidney disease.
Answers are grounded in this paper and cite their sources.
Renal denervation merits randomized trials in CKD; current evidence leaves open optimal patient selection and long-term safety.
Renal denervation (RDN) is an emerging minimally invasive technique that has been approved as an adjunctive therapy for resistant hypertension. Sympathetic activation is a shared pathological mechanism of hypertension and chronic kidney disease (CKD), and the kidney plays a crucial role in mediating this process. In recent years, RDN has demonstrated promising therapeutic potential for the management of patients with CKD. However, this technique still faces challenges such as heterogeneous efficacy and potential safety concerns. This review comprehensively summarizes the latest advances in the efficacy and safety of RDN in patients with CKD, and proposes critical perspectives to address the existing challenges.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) conducted a review in Chronic kidney disease (CKD) and resistant hypertension. Renal denervation (RDN) was evaluated on Efficacy and safety of renal denervation in chronic kidney disease. Renal denervation shows promising therapeutic potential for managing chronic kidney disease, though challenges of heterogeneous efficacy and safety concerns remain.
Synapse has enriched 10 related papers. Consider them for comparative context: